The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques Free

Abstract

Poxvirus vectors represent promising human immunodeficiency virus (HIV) vaccine candidates and were a component of the only successful HIV vaccine efficacy trial to date. We tested the immunogenicity of a novel recombinant capripoxvirus vector, lumpy skin disease virus (LSDV), in combination with modified vaccinia Ankara (MVA), both expressing genes from HIV-1. Here, we demonstrated that the combination regimen was immunogenic in rhesus macaques, inducing high-magnitude, broad and balanced CD4 and CD8 T-cell responses, and transient activation of the immune response. These studies support further development of LSDV as a vaccine vector.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.067835-0
2014-10-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/95/10/2267.html?itemId=/content/journal/jgv/10.1099/vir.0.067835-0&mimeType=html&fmt=ahah

References

  1. Amara R. R., Nigam P., Sharma S., Liu J., Bostik V. 2004; Long-lived poxvirus immunity, robust CD4 help, and better persistence of CD4 than CD8 T cells. J Virol 78:3811–3816 [View Article][PubMed]
    [Google Scholar]
  2. Aspden K., Passmore J. A., Tiedt F., Williamson A. L. 2003; Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol 84:1985–1996 [View Article][PubMed]
    [Google Scholar]
  3. Barouch D. H. 2010; Novel adenovirus vector-based vaccines for HIV-1. Curr Opin HIV AIDS 5:386–390 [View Article][PubMed]
    [Google Scholar]
  4. Borthwick N., Ahmed T., Ondondo B., Hayes P., Rose A., Ebrahimsa U., Hayton E. J., Black A., Bridgeman A.other authors 2013; Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1. Mol Ther 22:464–475 [View Article][PubMed]
    [Google Scholar]
  5. Burgers W. A., Shephard E., Monroe J. E., Greenhalgh T., Binder A., Hurter E., Van Harmelen J. H., Williamson C., Williamson A.-L. 2008; Construction, characterization, and immunogenicity of a multigene modified vaccinia Ankara (MVA) vaccine based on HIV type 1 subtype C. AIDS Res Hum Retroviruses 24:195–206 [View Article][PubMed]
    [Google Scholar]
  6. Burgers W. A., Chege G. K., Muller T. L., van Harmelen J. H., Khoury G., Shephard E. G., Gray C. M., Williamson C., Williamson A. L. 2009; Broad, high-magnitude and multifunctional CD4+ and CD8+ T-cell responses elicited by a DNA and modified vaccinia Ankara vaccine containing human immunodeficiency virus type 1 subtype C genes in baboons. J Gen Virol 90:468–480 [View Article][PubMed]
    [Google Scholar]
  7. Chege G. K., Burgers W. A., Stutz H., Meyers A., Chapman R., Kiravu A., Bunjun R., Shephard E. G., Jacobs W. R.other authors 2013; Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model. J Virol 87:5151–5160 [View Article][PubMed]
    [Google Scholar]
  8. de Cassan S. C., Draper S. J. 2013; Recent advances in antibody-inducing poxviral and adenoviral vectored vaccine delivery platforms for difficult disease targets. Expert Rev Vaccines 12:365–378 [View Article][PubMed]
    [Google Scholar]
  9. Garber D. A., O’Mara L. A., Gangadhara S., McQuoid M., Zhang X., Zheng R., Gill K., Verma M., Yu T.other authors 2012; Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques. J Virol 86:12605–12615 [View Article][PubMed]
    [Google Scholar]
  10. García-Arriaza J., Arnáez P., Gómez C. E., Sorzano C. O., Esteban M. 2013; Improving adaptive and memory immune responses of an HIV/AIDS vaccine candidate MVA-B by deletion of vaccinia virus genes (C6L and K7R) blocking interferon signaling pathways. PLoS ONE 8:e66894 [View Article][PubMed]
    [Google Scholar]
  11. Gómez C. E., Perdiguero B., García-Arriaza J., Esteban M. 2012a; Poxvirus vectors as HIV/AIDS vaccines in humans. Hum Vaccin Immunother 8:1192–1207 [View Article][PubMed]
    [Google Scholar]
  12. Gómez C. E., Perdiguero B., Nájera J. L., Sorzano C. O., Jiménez V., González-Sanz R., Esteban M. 2012b; Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV/AIDS vaccine candidate NYVAC-C in mice. J Virol 86:5026–5038 [View Article][PubMed]
    [Google Scholar]
  13. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., Robb M., Cox J., Michael N.other authors 2009; Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27:4468–4474 [View Article][PubMed]
    [Google Scholar]
  14. Haynes B. F., Gilbert P. B., McElrath M. J., Zolla-Pazner S., Tomaras G. D., Alam S. M., Evans D. T., Montefiori D. C., Karnasuta C.other authors 2012; Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275–1286 [View Article][PubMed]
    [Google Scholar]
  15. Keefer M. C., Frey S. E., Elizaga M., Metch B., De Rosa S. C., Barroso P. F., Tomaras G., Cardinali M., Goepfert P., Kalichman A. 2011; A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects. Vaccine 29:1948–1958 [View Article][PubMed]
    [Google Scholar]
  16. Kibler K. V., Gomez C. E., Perdiguero B., Wong S., Huynh T., Holechek S., Arndt W., Jimenez V., Gonzalez-Sanz R.other authors 2011; Improved NYVAC-based vaccine vectors. PLoS ONE 6:e25674 [View Article][PubMed]
    [Google Scholar]
  17. Kitching R. P., Hammond J. M., Taylor W. P. 1987; A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci 42:53–60[PubMed]
    [Google Scholar]
  18. Koff W. C., Burton D. R., Johnson P. R., Walker B. D., King C. R., Nabel G. J., Ahmed R., Bhan M. K., Plotkin S. A. 2013; Accelerating next-generation vaccine development for global disease prevention. Science 340:1232910 [View Article][PubMed]
    [Google Scholar]
  19. McElrath M. J., De Rosa S. C., Moodie Z., Dubey S., Kierstead L., Janes H., Defawe O. D., Carter D. K., Hural J.other authors 2008; HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case–cohort analysis. Lancet 372:1894–1905 [View Article][PubMed]
    [Google Scholar]
  20. Penaloza-MacMaster P., Provine N. M., Ra J., Borducchi E. N., McNally A., Simmons N. L., Iampietro M. J., Barouch D. H. 2013; Alternative serotype adenovirus vaccine vectors elicit memory T cells with enhanced anamnestic capacity compared to Ad5 vectors. J Virol 87:1373–1384 [View Article][PubMed]
    [Google Scholar]
  21. Perdiguero B., Gómez C. E., Di Pilato M., Sorzano C. O., Delaloye J., Roger T., Calandra T., Pantaleo G., Esteban M. 2013; Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV/AIDS vaccine candidate NYVAC-C. PLoS ONE 8:e74831 [View Article][PubMed]
    [Google Scholar]
  22. Quinn K. M., Da Costa A., Yamamoto A., Berry D., Lindsay R. W., Darrah P. A., Wang L., Cheng C., Kong W. P.other authors 2013; Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 190:2720–2735 [View Article][PubMed]
    [Google Scholar]
  23. Rerks-Ngarm S., Pitisuttithum P., Nitayaphan S., Kaewkungwal J., Chiu J., Paris R., Premsri N., Namwat C., de Souza M.other authors 2009; Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361:2209–2220 [View Article][PubMed]
    [Google Scholar]
  24. Shen Y. J., Shephard E., Douglass N., Johnston N., Adams C., Williamson C., Williamson A. L. 2011; A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV). Virol J 8:265 [View Article][PubMed]
    [Google Scholar]
  25. Shephard E., Burgers W. A., Van Harmelen J. H., Monroe J. E., Greenhalgh T., Williamson C., Williamson A. L. 2008; A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice. AIDS Res Hum Retroviruses 24:207–217 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.067835-0
Loading
/content/journal/jgv/10.1099/vir.0.067835-0
Loading

Data & Media loading...

Most cited Most Cited RSS feed